The
study analyzed that the Beta
Secretase inhibitors pipeline
comprised 15 drug candidates, of which three products are in Phase III, three
products in Phase II, one product in Phase I, and one product is in Discovery. The development of two
BACE inhibitor candidates was found to be inactive, and five products were
discontinued. BACE is a
cleaving enzyme of aspartyl protease with beta-secretase activity. It acts as a
precursor of beta-amyloid (Aβ) protein. In Alzheimer’s disease, the Aβ protein
fragments get accumulated in plaques in the brain. BACE initiates Aβ production
by cleaving amyloid precursor protein (APP) to generate APPβ and C99, which is
critical for the subsequent cleavage of C99 by gamma-secretase to release
Aβ1-40 and Aβ1-42. Inhibition of BACE enzyme disrupts the production of toxic
Aβ and formed plaque and new soluble oligomers.
Browse
the Report Summary at: https://www.psmarketresearch.com/market-analysis/beta-secretase-inhibitors-pipeline-analysis
Insights
on pipeline segments
As
per the findings of the research, around 80% pipeline drug candidates of BACE
inhibitors are being developed to be administered by oral route and 7% by
intravenous route. Most of the therapeutic candidates are being developed to be
administered by oral route due to high patient compliance.
Alzheimer’s disease drug
development receives Fast Track designation
Among
BACE inhibitors, AZD3293, a drug candidate of AstraZeneca plc and Eli Lilly and
Company, received Fast Track designation by the U.S. Food and Drug
Administration (FDA) in August 2016. The FDA’s Fast Track program was designed
to expedite the development and review new therapies to treat serious
conditions and tackle unmet medical needs.
Some of the key players developing BACE inhibitors are AstraZeneca plc, Eli Lilly & Company, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Eisai & Co., Ltd., CoMentis, Inc., vTv Therapeutics, Inc., Pfizer Inc., F. Hoffmann-La Roche Ltd., and Boehringer Ingelheim GmbH.
No comments:
Post a Comment